Complete Story
encorafenib (BRAFTOVI™) capsules, and binimetinib (MEKTOVI®) tablets Approved
Array BioPharma Inc., is pleased to announce that the U.S. Food and Drug Administration has approved encorafenib (BRAFTOVI™) capsules, and binimetinib (MEKTOVI®) tablets, as an oral combination therapy for patients with unresectable or metastatic melanoma with a BRAF V600E/K mutation as detected by an FDA-approved test. BRAFTOVI is not indicated for the treatment of patients with wild-type BRAF melanoma.
Kindly provide notification of approval to your membership. A link to company press release is below.
https://www.multivu.com/players/English/8336151-array-biopharma-braftovi-mektovi-fda-approval/
Full Prescribing information, available at:
